Objective: To investigate the effective symptomatic support therapy for children with septic encephalopathy. Methods: Totally 100 children with septic encephalopathy admitted into ICU of our hospital from Jan. 2018 to May 2019 were extracted to be divided into the observation group and the control group via the random number table

with 50 cases in each group. The control group received naloxone

while the observation group was given naloxone combined with dexmedetomidine

both groups were treated for 7 d. The levels of S100β protein

cerebral oxygen metabolism indicators such as regional cerebral oxygen saturation (rSO2)

internal jugular venous blood oxygen saturation (SjvO2)

internal jugular venous oxygen content difference (Da-jvO2)

cerebral oxygen metabolism rate (CERO2) and acute physiology before treatment (T0)

after treatment of 1 d (T1)

after treatment of 3 d (T2) and chronic health evaluation Ⅱ (APACHEⅡ)

Glasgow score before and after treatment of two groups were observed. Results: There was no statistically significant difference in serum S100β

rSO2

SjvO2

Da-jvO2 and CERO2 levels at T0 between two groups (P>0.05). The levels of S100β

Da-jvO2 and CERO2 in the observation group at T1

T2 and T3 were lower than those in the control group

and the levels of rSO2 and SjvO2 in the observation group were higher than those in the control group (P<0.05). After treatment

the APACHEⅡ score of the observation group was lower than that of the control group

and the Glasgow score was higher than that of the control group (P<0.05). Conclusion: Naloxone combined with dexmedetomidine can reduce the level of S100β protein in children with septic encephalopathy and maintain the balance of cerebral oxygen metabolism.